Nothing has changed. A newspaper reported that a plan is being drafted.
On October 7, 2026 the Washington Post reported that the administration is crafting plans to allow the temporary sale of certain previously restricted peptides while federal health officials write new regulations. The report is by Rachel Roubein and cites two people familiar with the matter, speaking anonymously to share private details. The plan has not been announced, timing was unclear, and the report says it could still change.1
What is in force today is unchanged. BPC-157 cannot legally be compounded, and nothing in the report alters that. The reason is narrower than most coverage states, and the section below sets it out.
Four separate things are being blurred together in coverage of this, and the rest of this page keeps them apart: what was reported, what is actually in force, what the July advisory vote did, and what "enforcement discretion" would and would not mean.
Two details from the FDA's own record sharpen all of it. The use the agency evaluated for BPC-157 was ulcerative colitis.2 Not tendons, not injury recovery, not gut healing in general. If BPC-157 were ever added to the list, that is the use it would be added for.
And against three of the six compounds the committee recommended, the FDA's safety page states that it has identified no human exposure data at all, by any route.3
What was actually reported?
A plan in drafting, described to one newspaper by two people who would not be named.
The report describes a move that would let some compounding pharmacies dispense certain peptides marketed as new medical treatments and wellness products, even though the claims for what they treat have not been fully safety tested. It states that the plan has not yet been announced, that timing was unclear, and that it is not immediately clear which peptides the administration is aiming to make temporarily available.1
The political context is in the report and belongs here. Health Secretary Robert F. Kennedy Jr. is described as a self-professed big fan of peptides who has said he wants to make them more broadly available.1 That is the force behind this, and it is why coverage of a drafted plan carries the weight it does.
Three things in the report get separated out from the headline below.
FDA scientists are on the other side of it. The Post reports that in late June, FDA career scientists said there is not enough evidence on the effectiveness and safety of these peptides to allow production by compounding pharmacies, and that during the advisory sessions the agency's scientists urged the panel to vote against them.1
The mechanism was requested by the industry. Scott Brunner of the Alliance for Pharmacy Compounding told the Post his trade group has been asking the FDA to use interim enforcement discretion, and that he has met the agency twice to set out the approach, with conditions including enhanced patient disclosures, serious adverse event reporting and data collection on peptide use.1
And the panel that recommended them was itself contested. The Post reports the advisory committee included multiple people who promote peptides or work for companies that sell them, that agency officials had raised potential conflict-of-interest concerns while HHS was assembling the panel, and that FDA staff typically choose their own advisers. An FDA spokesman previously defended the members as having undergone the same ethics and vetting process required of all advisory committee members.1
So the chain is: a plan not yet written, described by two anonymous sources, reported by one outlet, over the stated objections of the agency's own scientists, arriving at a reader as "pharmacies can compound BPC-157 now".
Is BPC-157 still banned from compounding?
It cannot legally be compounded, and the reason is not the one most coverage gives.
What changed, and it is not what the coverage says. BPC-157 was in Category 2 of the interim policies, the designation for bulk substances the FDA has identified as possibly presenting significant safety risks. It is no longer in that table.
It now appears in a second table on the same FDA page, headed bulk drug substances nominated but withdrawn. The page states that the substances listed there were previously in category 2 and were withdrawn by the nominators.3
So BPC-157 did not leave the significant-safety-risk category because the FDA reassessed it. It left because whoever nominated it pulled the nomination. Vendor and clinic pages describing this as the FDA removing peptides from Category 2 are describing a clearance that did not happen.
The FDA still publishes its safety concern for every one of them. Against BPC-157, the current page states that compounded drugs containing it may pose a risk for immunogenicity for certain routes of administration and may have complexities regarding peptide-related impurities and active ingredient characterisation, that the agency has identified no or only limited safety-related information for the proposed routes, and that it therefore lacks sufficient information to know whether the drug would cause harm when administered to humans.3
That text sits on the page today, beside the compound, under a heading about significant safety risks.
And for three of the compounds the committee recommended, the FDA says there is no human exposure data at all. Against TB-500, KPV and MOTS-c the page states, in each case, that the FDA has not identified any human exposure data on drug products containing the substance administered via any route of administration.3
Those three were among the six the advisory committee voted to recommend.
Why leaving the category did not make it compoundable. The categories are an interim sorting system for substances nominated for the Bulks List. They are not the eligibility test.
The FDA states the test plainly: a bulk drug substance may be used in compounding under Section 503A if it has an applicable USP or NF monograph, or is a component of an FDA-approved drug product, or appears on the 503A Bulks List where neither of the first two applies.4 BPC-157 satisfies none of the three.
So withdrawing a nomination removes a substance from the queue. It does not put it on the list.
So it is no longer barred as a safety risk, and it has not been cleared either. It sits outside the exemption, in a position that is functionally the same as being restricted and legally quite different from it.
And the FDA's own position going into July was against listing it. The agency's briefing document for the advisory meeting states that FDA is proposing that BPC-157 free base not be included on the 503A Bulks List, and the same for BPC-157 acetate and for TB-500 in both forms.5 That document is on fda.gov; we read those lines through a search index rather than by opening the PDF, so the wording is the agency's and the reading is one step removed.
That is the detail most coverage leaves out. The committee that recommended six of seven was voting against its own agency's proposal.
Did the July vote make these peptides legal?
No. It was a recommendation from an advisory committee, and the FDA says in its own words that such recommendations are not binding.
On July 23 and 24, 2026, the Pharmacy Compounding Advisory Committee discussed seven substances for possible inclusion on the 503A Bulks List. The FDA's agenda names all seven, and the uses it evaluated for each.2
| Substance | Use the FDA evaluated |
|---|---|
| BPC-157 | Ulcerative colitis |
| KPV | Wound healing and inflammatory conditions |
| TB-500 | Wound healing |
| MOTS-c | Obesity and osteoporosis |
| Emideltide, also called DSIP | Opioid withdrawal, chronic insomnia and narcolepsy |
| Semax | Cerebral ischemia, migraine and trigeminal neuralgia |
| Epitalon | Insomnia |
Seven were discussed and six were recommended. The committee voted against emideltide, which is DSIP. Secondary summaries that give six as the total are counting the recommendations; those that give seven are counting the agenda. Both numbers are correct about different things.
Three things that vote was not.
Not binding. The FDA's own page states that advisory committees make non-binding recommendations, which the agency generally follows but is not legally bound to do.2
Not a rule. Any change has to be published as a proposed rule with a public comment period before it takes effect.
Not drug approval. Adding a substance to the 503A Bulks List means a pharmacy may use it in a compounded preparation. It does not mean the compound has been found safe or effective, and it does not make it an approved drug. Our guide on the July vote covers what the record showed.
What does enforcement discretion actually mean?
It is a decision not to act, which is a different thing from permission.
Enforcement discretion is the FDA saying it does not currently intend to take action against a particular practice. The practice remains unlawful. The agency is declining to pursue it, for stated reasons, for as long as it chooses.
There is a recent example, and its ending is the instructive part. During the semaglutide and tirzepatide shortages, compounding of those drugs was permitted under shortage provisions. When the shortages were declared over, that window closed and compounders were given deadlines to stop. Our guide on compounded semaglutide covers what changed and when.
So the shape of enforcement discretion is: it starts when an agency decides, it ends when an agency decides, and the underlying legal status never changed in between. Anyone who built a business or a treatment plan on the first part discovered the second.
It is also not the same as the Bulks List. A listing is a durable regulatory change arrived at through rulemaking. Enforcement discretion is a posture. The reported plan is the second, used as a bridge while the first is being written.
It is also what the compounding industry asked for. The Post reports that the Alliance for Pharmacy Compounding has been seeking interim enforcement discretion specifically, with conditions attached, and that a peptide trade body commissioned polling from a firm run by the president's pollster, with a memo viewed by the Post describing a political upside to allowing access at regulated US pharmacies.1 Whatever one makes of that, it is not a case of a regulator acting unprompted.
What would change for someone buying today?
Less than the headlines suggest, and nothing yet.
Today: nothing has changed. Research-labelled vials bought from online sellers are in exactly the position they were in last week. Our guide on what research use only means covers that position.
If the stopgap happens: compounding pharmacies could dispense certain peptides on a prescription, with a prescriber involved, from pharmaceutical-grade ingredients, with the pharmacy accountable for sterility and potency. That is a materially different supply chain from a vial posted from an unverified seller.
It would not make research-labelled vials legal, approved or tested. It would create a parallel route, not legitimise the existing one.
Two things about that parallel route. It requires a prescription, so it means a clinician, an appointment and a cost. And the uses would be the ones the FDA evaluated, which for BPC-157 means ulcerative colitis rather than a torn tendon.
And one thing nobody can tell you: whether it happens, when, which compounds, or for how long. A drafted plan reported by two unnamed people is not a date.
Common questions
Can pharmacies compound BPC-157 right now?
No. BPC-157 is not on the 503A Bulks List, has no USP monograph and is not a component of an approved drug, so compounding it falls outside the Section 503A exemption. It has left the Category 2 table, but the FDA's page records that as the nomination being withdrawn rather than the substance being cleared, and the page still publishes its safety concern against BPC-157 today.
What did the Washington Post actually report?
That the administration is crafting plans to allow temporary sale of certain previously restricted peptides through compounding pharmacies while new regulations are written, citing two people familiar with the matter. The report states the plan has not yet been announced, timing was unclear, it could still change, and it was not immediately clear which peptides are involved. It also reports that FDA career scientists said in late June there is not enough evidence to allow their production, and that agency scientists urged the advisory panel to vote against them.
Why is this happening now?
Health Secretary Robert F. Kennedy Jr. has described himself as a big fan of peptides and has said he wants them more broadly available. The compounding industry has separately been asking the FDA for interim enforcement discretion, and a peptide trade body commissioned polling arguing there is political upside to expanding access through regulated pharmacies.
Is the peptide ban being lifted?
Partly, and the word ban is doing a lot of work. BPC-157 has moved from the FDA's Category 2 table to a second table on the same page headed "nominated but withdrawn", which the page says means the nominators withdrew it. The FDA's safety concern against BPC-157 is still published there. Compounding still falls outside the Section 503A exemption because the compound has no monograph, is not a component of an approved drug, and is not on the Bulks List.
Was it six peptides or seven?
Seven were discussed at the July advisory committee meeting and six were recommended. The committee voted against emideltide, which is DSIP. The FDA's own meeting agenda lists all seven.
Did the FDA approve these peptides?
No, and the agency's own staff proposed against listing them. The FDA's briefing document for the July meeting states it is proposing that BPC-157 and TB-500 not be included on the 503A Bulks List. The advisory committee then made a non-binding recommendation the other way. That is not drug approval, and the FDA states it is not legally bound to follow such advice.
What is enforcement discretion?
A decision by the FDA not to pursue action against a practice that remains unlawful. It is permission in practice and not in law, it starts and ends at the agency's discretion, and compounded GLP-1s during the recent shortages are the clearest recent example of it being used and then withdrawn.
Would this make research peptides legal?
No. It would create a route through licensed compounding pharmacies on a prescription. Vials sold as research chemicals would be in the same position they are in now.
What use was BPC-157 actually evaluated for?
Ulcerative colitis. That is the use named on the FDA's meeting agenda, and it is not what most people buying BPC-157 are using it for.
When will we know?
There is no date. The report describes a plan that has not been announced, with unclear timing, that could still change.
Sources
- Roubein R. Trump administration paving way for temporary sale of some unapproved peptides. Washington Post, October 7, 2026. washingtonpost.com. Read in full. Reports that the administration is crafting plans to allow temporary sale of certain previously restricted peptides while federal health officials write new regulations, according to two people familiar with the matter speaking on condition of anonymity. States the plan has not yet been announced, timing was unclear, it could still change, and it was not immediately clear which peptides are involved. Reports that in late June FDA career scientists said there is not enough evidence on effectiveness and safety to allow production by compounding pharmacies, and that during the advisory sessions agency scientists urged the panel to vote against the peptides. Records that the advisory committee included multiple people who promote peptides or work for companies that sell them, that agency officials had expressed potential conflict-of-interest concerns while HHS assembled the panel, that FDA staff typically choose their own advisers, and that an FDA spokesman previously defended the members as having undergone the standard ethics and vetting process. Quotes Scott Brunner of the Alliance for Pharmacy Compounding describing the trade group's request for interim enforcement discretion, with conditions including enhanced patient disclosures, serious adverse event reporting and data collection, and two meetings with the FDA to set out that approach. Notes the panel voted against emideltide, proposed to treat opioid withdrawal and insomnia, and recommended six of the seven. Reports that the American Academy of Peptide Medicine commissioned polling from a firm run by the president's pollster, with a memo viewed by the Post describing a political upside to boosting access at regulated US pharmacies, and quotes its chairman Lee Rosebush urging HHS to use temporary enforcement discretion. HHS did not comment.
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov. Primary source, read directly. The meeting agenda lists seven bulk drug substances considered for inclusion on the 503A Bulks List, each in free base and acetate forms, with the uses the FDA evaluated: BPC-157 for ulcerative colitis; KPV for wound healing and inflammatory conditions; TB-500 for wound healing; MOTS-c for obesity and osteoporosis; emideltide, also referred to as delta sleep-inducing peptide or DSIP, for opioid withdrawal, chronic insomnia and narcolepsy; semax for cerebral ischemia, migraine and trigeminal neuralgia; epitalon for insomnia. The page states that advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so. Public docket FDA-2025-N-6895.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov. Page content current as of April 22, 2026. Read in full. The page states that bulk drug substances which may present significant safety risks have been placed in category 2 under the interim policies, and carries two tables. The first lists substances currently under category 2, including ibutamoren mesylate, kisspeptin-10, GHRP-2, GHRP-6 and ipamorelin acetate. The second is headed "Bulk drug substances nominated but withdrawn" and states that the substances listed there were previously in category 2 of the interim policies and were withdrawn by the nominators. That second table includes AOD-9604, BPC-157, cathelicidin LL-37, CJC-1295, dihexa acetate, emideltide (DSIP), epitalon, GHK-Cu for injectable routes, ipamorelin acetate (which also appears in the first table under the 503B interim policy), KPV, PEG-MGF, melanotan II, MOTs-C, selank acetate, semax, thymosin-alpha 1 and thymosin beta-4 fragment (TB-500). The FDA's stated safety concern is retained against each. For BPC-157: may pose risk for immunogenicity for certain routes of administration and may have complexities regarding peptide-related impurities and API characterisation; FDA has identified no, or only limited, safety-related information for the proposed routes of administration; therefore the agency lacks sufficient information to know whether the drug would cause harm when administered to humans. For TB-500, KPV, MOTs-C and PEG-MGF the page states in each case that FDA has not identified any human exposure data on drug products containing the substance administered via any route of administration.
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov. States that a bulk drug substance may be used in compounding under section 503A if it has an applicable USP or NF monograph, is a component of an FDA-approved drug product, or appears on FDA's list of bulk drug substances that can be used in compounding where such a monograph does not exist and the substance is not a component of an approved drug. Describes the interim policy's three categories for nominated substances, which are a sorting mechanism during evaluation rather than the eligibility test itself.
- U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee, FDA Briefing Document Introduction. fda.gov. FDA document, on fda.gov. The quoted lines were read through a search index rather than by opening the PDF directly, so the wording is the agency's and the reading is one step removed; confirm by opening the document before quoting elsewhere. States that FDA is proposing that BPC-157 free base not be included on the 503A Bulks List, that BPC-157 acetate not be included, and the same for TB-500 free base and TB-500 acetate. The agency's scientific staff therefore entered the meeting recommending against the substances the committee went on to recommend.
Citing this page. Peptide Decoding. Can Pharmacies Compound BPC-157 Now? Agenda and evaluated uses from the FDA meeting record of July 23-24, 2026. https://peptidedecoding.com/news/bpc-157-compounding-stopgap